68results about "Nitro compound active ingredients" patented technology

A method for treating cancer or a tumor, in particular treating cancer by combining two drugs, relating to the field of cancer treatment. A method for treating cancer by combining a drug containing an AKR1C3 enzyme-activated compound and an immune checkpoint inhibitor / immune cell treatment drug. In particular, the immune checkpoint inhibitor is selected from an anti-PD -1 antibody, an anti-PD-L1 antibody, an anti-CTLA-4 antibody, etc., and the AKR1C3 enzyme-activated compound is selected from the compound of the following structure (I).

The invention provides a phenoxy (hetero) aryl ether with anti-proliferative activity. The invention of the present application includes novel aromatic molecules useful in the treatment of pathological conditions, such as cancer, skin diseases, muscle disorders, and immune system-related disorders, such as disorders of the hematopoietic system, including the blood system, in human and veterinary medicine.

Disclosed are Type II Topoisomerase Inhibitors, analogs thereof, pharmaceutical compositions thereof, and methods of making and using these compounds and compositions. Methods of using the disclosed compounds to treat infections, such as MRSA are also described.

Described herein are methods for predicting treatment response to glutamate modulating agents, selecting treatment comprising glutamate modulating agents, for, and treating subjects with glutamate modulating agents, in subjects with autism spectrum disorder (ASD).

Provided here are compositions and methods for treatment of vascular conditions or respiratory conditions by administering a therapeutically effective amount of a nitrogen oxide compound and a nitrodilator. The nitrogen oxide compound can be nitrite, one or more of a number of nitro-group containing compounds, a nitrate-group containing compound, an NO donor, or an endogenous NO producing amino acid. The nitrodilator can be one or more of nitroglycerin, isosorbide dinitrate, isosorbide mononitrate, nitroprusside, amyl nitrite, nitrosothiols, or dinitrosyl iron complexes.

The invention relates to a skin-compatible, nourishing, and protective agent for application to or treatment of the skin, comprising one or more active substances, in particular, but not exclusively, plant extracts or oils. According to the invention, a first mixture component is provided, which contains at least almond oil, cetyl alcohol, CBD isolate, and vitamin E or tocopherol, and a second mixture component is provided, which comprises sea salt dissolved in purified water, as well as xanthan gum and propylene glycol, wherein the first and second mixture components are combined and emulsified.

The present invention provides compounds that are useful as modulators of the cannabinoid receptor 2 (CB2R) having the general formula (I), wherein R1 to R3 are as described herein, compositions including the compounds, processes of manufacturing the compounds and methods of using the compounds.

A method for treating BRCA gene-mutated cancer. In the method, a drug containing hypoxia-activated prodrug compounds of formulas (1), (2) and (3) or AKR1C3 enzyme-activated prodrug compounds of formulas (4), (5), (6), (7), (8), (9), (10), (11) and (12) and salts, esters, solvates and isotopic isomers thereof, is used alone or in combination with other drugs to treat patients with BRCA gene-mutated cancer and tumors.

The invention relates to an AKR1C3 enzyme expression level and medical application through KRAS mutation. According to the AKR1C3 enzyme activated anticancer prodrug, KRAS gene mutation can be directly used as a detection target before medication, namely, a KRAS mutation patient is a patient with high expression of the AKR1C3 enzyme and does not need to be subjected to AKR1C3 enzyme expression level or AKR1C3RNA detection, that is to say, KRAS mutation detection positive can be used as a screening index to screen the patient with high expression of the AKR1C3 enzyme.

The present invention relates generally to methods and compositions useful for delivering a visually colorless topical composition comprising resveratrol and chamomile.

Described herein are articles comprising a nitric oxide releasing compound and dextran bonded to at least one surface of the article, wherein a sulfonated triazine is covalently bonded to dextran. In one aspect, the articles bind to albumin, which can reduce clotting at the surface of the article and the risk of thrombosis.

Disclosed herein are antimicrobial compounds compositions, pharmaceutical compositions, the method of use and preparation thereof. Some embodiments relate to boronic acid derivatives and their use as therapeutic agents, for example, β-lactamase inhibitors (BLIs).

Within the scope of the invention, 18 novel 3,5-disubstituted-1,2,4-oxadiazole derivative compounds were synthesized. The synthesized compounds were found to have high inhibitory activity on carbonic anhydrase enzymes I and II (CA I and CA II).

The present invention provides the use of entacapone, an entacapone derivative, or a stereoisomer, hydrate, or pharmaceutically acceptable salt thereof, in a human in need thereof for treating an injury or promoting wound healing or tissue regeneration.

Described herein are methods for predicting treatment response to glutamate modulating agents, selecting treatment comprising glutamate modulating agents, for, and treating subjects with glutamate modulating agents, in subjects with autism spectrum disorder (ASD).

The invention pertains to the use of therapeutically effective amounts of (i) one or more of uridine and cytidine, or salts, phosphates, acyl derivatives or esters thereof; and(ii) at least one of docosahexaenoic acid (22:6; DHA), eicosapentaenoic acid (20:5; EPA) and docosapentaenoic acid (22:5; DPA), or esters thereof; and (iii) vitamin C and / or selenium, optionally in combination with vitamin E, in the manufacture of a product for therapeutically preventing and / or slowing down brain atrophy in a human subject in need thereof.

Provided herein are methods of treating vaginitis by simultaneous local application per vagina of both boric acid and nitroimidazole. Also provided are compositions useful in such treatments, for instance containing 100-1,000 mg of nitroimidazole and 300-900 mg boric acid. Vaginal application of nitroimidazole allows a higher but safe dose to be administered simultaneously with boric acid for the effective treatment of bacterial vaginosis (BV). Also provided are methods for prophylactic treatment of patients, such as those prone to recurrent BV.

Clostridium difficile infection (CDI) is a public health threat that results in 14,000 annual deaths in the United States. Challenges involve the production of CDI spores that can remain dormant for years and the production of toxins that damage the gut. Current therapies for CDI include vancomycin and metronidazole, but neither inhibits spore or toxin production. Thus, recurrence of infection occurs in 25% of patients and there are no antibiotics that are effective for multiple recurrences. We describe oxadiazoles with activity against C. difficile, including the highly virulent NAP1 / 027 strain with increased production of toxins A and B, as well as the additional binary toxin. Oxadiazole 2 is poorly absorbed, thus advantageously achieving high concentrations in the gut. The compound targets peptidoglycan synthesis and inhibits vegetative cells, spores, and toxin production.

The disclosure provides methods, treatments and materials for enhancing the effect of an adenosine A2 receptor agonist in the treatment, mitigation or prophylaxis of a disease or condition characterized by inotropic and / or lusitropic dysfunction, and / or enhancing adenosine A2 receptor function in the treatment, mitigation or prophylaxis of a disease or condition characterized by impaired adenosine A2 receptor function, comprising administration of an effective amount of a PDE1 inhibitor to a patient in need thereof, for example a patient suffering from heart failure.

The present application relates to methods and compositions for treating epileptic disorders. The use of allosteric modulators and / or gaboxadol for treating an epileptic disorder in a subject in need thereof.

The present invention comprises novel aromatic molecules, which can be used in the treatment of pathological conditions, such as cancer, skin diseases, muscle disorders, and immune system-related disorders such as disorders of the haematopoietic system including the haematologic system in human and veterinary medicine.

Described herein are compounds that reactivate acetylcholinesterase and associated methods of treating organophosphate poisoning.

The present invention relates to the combination of meropenem and one or more antibiotic resistance breakers, pharmaceutical compositions containing the same, and methods for treating bacterial infections that include administering the same. Particularly, it relates to a pharmaceutical composition comprising (a) meropenem, (b) avibactam, and (c) EDTA.

The present invention relates generally to nitric oxide (NO) releasing nasal compositions and methods of use thereof.

A solid powder composition comprising an agglomerate of particles, the agglomerate comprising: (i) particles comprising nitrite and one or more proton sources; or (ii) particles comprising one or more nitrites and one or more proton sources. Also disclosed are pharmaceutical compositions comprising the solid powder composition, methods of making the solid powder composition, materials and devices comprising the solid powder composition, methods of making same and methods of implanting same in the human or animal body.

Provided herein are compositions, systems, kits, and methods for applying a composition topically to a bodily area of a subject that has precancerous and / or cancerous cells (e.g., skin cancer cells) and / or is adjacent to underlying precancerous and / or cancerous cells, where the composition comprises N-phosphonacetyl-L-aspartate (PALA) (aka sparfosic acid) and water, and optionally further comprises at least one non-ionic surfactant.

The invention discloses an injection preparation, compatible liquid medicine and a preparation method thereof. The injection preparation and the compatible liquid medicine provided by the invention meet the requirements of long-term clinical tests and commercial production and sales through tests. The injection preparation is a solution containing a compound shown in the formula I, and a solvent of the solution contains C2-C8 alcohol and can also contain other cosolvents or solubilizers. A preferable injection preparation is a mixed solution containing 10mg / ml of the compound shown in the formula (I), DMA, ELP and ethanol, DMA is a cosolvent, and ELP is a solubilizer. A solvent of the ready-to-use injection (compatible liquid medicine) of the compound shown in the formula (I) is water, solutes of the ready-to-use injection comprise the compound shown in the formula I, DMA, ELP, ethyl alcohol, an isotonic regulating reagent and a pH regulator, the concentration of the compound A in the injection is 0.016-1.10 mg / ml, the pH of the injection is 7.4, and the injection is an isotonic solution. In addition, the invention also discloses a preparation method of the injection preparation and the compatible liquid medicine thereof.

The present disclosure describes the use of 2,4-disulfonyl phenyl tert-butyl nitrone (2,4- ds-PBN) in the treatment of temozolomide drug resistant gliomas. The 2,4-ds-PBN may be used combined with other chemo- and radiotherapies and surgery, including temozolomide, to reduce glioma occurrence, recurrence, spread, growth, metastasis, and vascularization, and to inhibit development of temozolomide resistance.

Lactivicin compounds of formula (I) and pharmaceutically acceptable salts of the compounds of formula (I) are provided. wherein the compounds comprise antibiotics suitable for use either alone or in combination with β-lactamase inhibitors and / or other antibiotics (including β-lactam and non-β-lactam antibiotics) in the treatment or prevention of bacterial infections.